Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios

“…The MST of BR-PDAC patients with an NLR of >3 (n = 12) or a PLR of >225 (n = 8) was 10.2 months in each group. In recent phase II studies, the MST of patients with locally advanced UR-PDAC who received non-surgical treatment has been reported to be 13-17 months [32][33][34][35]. It is obviously not beneficial for these patients to undergo an "upfront" surgical approach.…”

Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial

“…Recently, clinical studies of CCRT with S-1 for locally advanced pancreatic cancer [25] and CRT with S-1 plus cisplatin for non-small cell lung cancer [26,27], and head and neck cancer [28] have been attempted. Sudo et al [25] reported that CCRT with S-1 showed a promising antitumor effect, with a response rate of 41% and an MST of 16.8 months with acceptable toxicity in patients with locally advanced pancreatic cancer.…”

“…Sudo et al [25] reported that CCRT with S-1 showed a promising antitumor effect, with a response rate of 41% and an MST of 16.8 months with acceptable toxicity in patients with locally advanced pancreatic cancer. CCRT with S-1 plus cisplatin for locally advanced non-small cell lung cancer has shown promising efficacy outcomes of 86.4-87.5% combined with good survival rates (24.4-33.1 months) and mild toxicity [26,27].…”

Clinical Results of Radiotherapy for Locally Advanced Stage III Pancreatic Cancer: A Single Institutional Experience

“…The median survival time of the patients with locally advanced pancreatic cancers that received chemoradiotherapy or radiotherapy alone or chemotherapy alone was found to be between 5.7-16.8 in a previous randomized controlled study [8][9][10][12][13][14][15][16]. In particular, the results of the median survival time with chemoradiotherapy with TS-1 had been 11-16.8 months [17][18][19][20][21][22]. Our study included 12 patients with TS-1 and a median survival time of 10.8 months, which is slightly inferior compared to previous reports.…”